The algorithm reads ECG data collected by Eko’s digital stethoscope to measure LVEF, which refers to the amount of blood pumped out of the heart’s left ventricle and can indicate heart failure. The breakthrough device label, presented to technology with potential to address unmet clinical needs, will speed up regulatory review of the algorithm.
Eko and Mayo Clinic’s partnership to develop the AI algorithm began in late 2018. Since then, studies have shown that the algorithm-equipped stethoscope achieves significant accuracy in detecting low ejection fraction. Mayo Clinic also joined Eko’s $20 million Series B funding round in September to advance the startup’s research.
More articles on AI:
St. Jude study: AI blood test improves infection predictions for leukemia patients
Memorial Sloan Kettering spinoff raises $45M for AI pathology platform
Physician viewpoint: AI use might lead to overdiagnosis of cancer
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.